Trial Profile

Pharmacokinetic Evaluations of Tabalumab Following Subcutaneous Administration by Prefilled syringe or Auto-Injector in Patients with Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate. [Farmakokinetické hodnocení tabalumabu po podkožním podání pomocí předplněné injekční stříkačky nebo autoinjektoru u pacientů s revmatoidní artritidou, kteří měli nedostačující odezvu na metotrexát].

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

07 Feb 2013 Status changed from suspended to discontinued, as reported in an Eli Lilly media release.
13 Dec 2012 Status changed from recruiting to suspended, as reported in an Eli Lilly media release.
12 Dec 2012 New source identified and integrated (European Clinical Trials Database, EudraCT2012-001618-40)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com